Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Apellis Pharmaceuticals Inc (APLS)

Apellis Pharmaceuticals Inc (APLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Apellis Pharmaceuticals Inc 100 FIFTH AVENUE WALTHAM MA 02451 USA

www.apellis.com Employees: 706 P: 617-977-5700

Description:

Apellis Pharmaceuticals, Inc. is a clinical-stage biotech focused on the development of novel therapeutics, which work through the inhibition of the complement system, specially targeting the C3 protein of the complement system to treat autoimmune and inflammatory diseases.

Key Statistics

Overview:

Market Capitalization, $K 4,131,091
Enterprise Value, $K 3,778,791
Shares Outstanding, K 124,393
Annual Sales, $ 396,590 K
Annual Net Income, $ -528,630 K
Last Quarter Sales, $ 196,830 K
Last Quarter Net Income, $ -57,450 K
EBIT, $ -223,330 K
EBITDA, $ -195,330 K
60-Month Beta 0.94
% of Insider Shareholders 6.80%
% of Institutional Shareholders 96.29%
Float, K 115,934
% Float 93.20%
Short Volume Ratio 0.55

Growth:

1-Year Return -39.57%
3-Year Return -32.45%
5-Year Return 15.55%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth -90.17%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.46 on 11/05/24
Next Earnings Date N/A
Earnings Per Share ttm -2.01
EPS Growth vs. Prev Qtr -64.29%
EPS Growth vs. Prev Year 60.68%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

APLS Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -103.11%
Return-on-Assets % -28.96%
Profit Margin % -133.29%
Debt/Equity 1.51
Price/Sales 10.39
Price/Cash Flow N/A
Price/Book 17.39
Book Value/Share 1.91
Interest Coverage -16.80
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar